Amova Asset Management Americas Inc. Has $41.02 Million Stock Position in GeneDx Holdings Corp. $WGS

Amova Asset Management Americas Inc. boosted its position in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 67.3% in the 1st quarter, HoldingsChannel reports. The firm owned 638,800 shares of the company’s stock after buying an additional 257,075 shares during the period. Amova Asset Management Americas Inc.’s holdings in GeneDx were worth $41,024,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Kestra Advisory Services LLC bought a new position in shares of GeneDx in the fourth quarter valued at approximately $27,000. Fifth Third Bancorp acquired a new stake in GeneDx during the 1st quarter valued at $31,000. Quarry LP raised its position in GeneDx by 248.8% in the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after purchasing an additional 209 shares during the last quarter. Ramirez Asset Management Inc. bought a new position in GeneDx in the 4th quarter valued at $33,000. Finally, Greenline Wealth Management LLC acquired a new position in GeneDx in the fourth quarter worth $33,000. 61.72% of the stock is owned by institutional investors.

Insider Buying and Selling at GeneDx

In related news, Director Keith A. Meister acquired 533,758 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was acquired at an average price of $37.86 per share, for a total transaction of $20,208,077.88. Following the completion of the acquisition, the director owned 3,761,908 shares of the company’s stock, valued at $142,425,836.88. This trade represents a 16.53% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Casdin Capital, Llc acquired 185,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was bought at an average price of $42.60 per share, with a total value of $7,881,000.00. Following the acquisition, the director directly owned 3,367,164 shares of the company’s stock, valued at $143,441,186.40. The trade was a 5.81% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders bought 2,256,420 shares of company stock worth $93,144,340 and sold 21,699 shares worth $1,295,646. 25.17% of the stock is owned by company insiders.

GeneDx Trading Down 4.5%

WGS opened at $60.65 on Tuesday. The firm has a 50 day simple moving average of $56.98 and a 200 day simple moving average of $73.97. GeneDx Holdings Corp. has a fifty-two week low of $32.21 and a fifty-two week high of $170.87. The company has a market cap of $1.80 billion, a price-to-earnings ratio of -22.63 and a beta of 1.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95.

GeneDx (NASDAQ:WGS) last released its earnings results on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The business had revenue of $102.25 million for the quarter, compared to analyst estimates of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same period in the prior year, the firm posted ($0.23) EPS. On average, sell-side analysts anticipate that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

Wall Street Analyst Weigh In

WGS has been the subject of a number of research reports. Canaccord Genuity Group set a $75.00 target price on GeneDx and gave the company a “buy” rating in a research note on Tuesday, May 5th. Piper Sandler reiterated an “overweight” rating and set a $63.00 price target (up from $50.00) on shares of GeneDx in a research report on Tuesday, June 23rd. Wells Fargo & Company reissued an “overweight” rating and set a $75.00 price objective (down from $155.00) on shares of GeneDx in a report on Tuesday, May 5th. TD Cowen restated a “buy” rating on shares of GeneDx in a research report on Wednesday, July 15th. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $85.00 target price on shares of GeneDx in a research note on Tuesday, May 5th. Seven research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $87.43.

Trending Headlines about GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: No clearly positive company-specific catalyst was reported in the latest filings and notices.
• Neutral Sentiment: Multiple law firms, including Rosen, Schall, Levi & Korsinsky, Faruqi & Faruqi, and Kahn Swick & Foti, reminded investors of an August 3, 2026 lead-plaintiff deadline in a securities class action covering purchases between April 16, 2025 and May 4, 2026. Article Title
• Neutral Sentiment: Hagens Berman said it is investigating claims that GeneDx misled investors about the Fabric Genomics acquisition and expected synergies, highlighting a prior 49% stock drop after the company’s Q1 2026 report and a $31.2 million impairment charge. Article Title
• Neutral Sentiment: Several additional firms issued similar class-action reminders, reinforcing the legal overhang rather than introducing new operational news. Article Title
• Negative Sentiment: The repeated lawsuit coverage and allegations of acquisition-related misrepresentations are likely weighing on sentiment and help explain why the stock is trading lower. Article Title

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.